Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor by Yamamoto, Keiko, MD, Tanabe, Nobuhiro, MD, PhD, FCCP, Suda, Rika, MD, PhD, Sasaki, Akane, MD, Matsumura, Akane, MD, Ema, Ryogo, MD, Kasai, Hajime, MD, PhD, Kato, Fumiaki, MD, PhD, Sekine, Ayumi, MD, PhD, Nishimura, Rintaro, MD, PhD, Jujo, Takayuki, MD, PhD, Sugiura, Toshihiko, MD, PhD, Shigeta, Ayako, MD, PhD, Sakao, Seiichiro, MD, PhD, Tatsumi, Koichiro, MD, PhD, FCCP

Get full text